List view / Grid view
24 April 2017 | By Niamh Marriott, Junior Editor
BMS-986036 is a pegylated analogue of human fibroblast growth factor 21, a key regulator of metabolism. In preclinical models of non-alcoholic steatohepatitis (NASH), BMS-986036 improved steatosis, inflammation, hepatocyte ballooning, and fibrosis.
24 April 2017 | By Niamh Marriott, Junior Editor
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype and compensated cirrhosis (Child-Pugh A)...
24 April 2017 | By Niamh Marriott, Junior Editor
After Danish and Swedish, Solidsoft Reply has signed an agreement to implement and operate the Irish National Medicines Verification System...
21 April 2017 | By Niamh Marriott, Junior Editor
Allergan will collaborate with TARGET PharmaSolutions, a clinical data company focused on real world evidence, on its TARGET-NASH study.
21 April 2017 | By Ingenza
Edinburgh-based Ingenza is celebrating after being named the Innovator of the Year at the 2017 Made in Scotland awards, held at the Glasgow Science Centre on the 19th of April...
21 April 2017 | By METTLER TOLEDO
METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks are proving advantageous for the University of Glasgow’s Centre for Cell Engineering, where scientists are investigating cell differentiation and behavior on a variety of materials...
21 April 2017 | By Niamh Marriott, Junior Editor
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy...
20 April 2017 | By Niamh Marriott, Junior Editor
Targovax has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer...
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis demonstrated that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved complete response at six months when treated...
20 April 2017 | By Wickham Laboratories
Wickham Laboratories Ltd will exhibit on Stand 309 at the Making Pharmaceuticals Conference on the 25th – 26th April 2017 at Ricoh Arena, Coventry...
20 April 2017 | By Aesica Pharmaceuticals
Product life cycle services expanded, including for high potent and controlled drugs...
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist...
19 April 2017 | By Niamh Marriott, Junior Editor
GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to...
19 April 2017 | By Munters
Munters, global leaders in energy efficient air treatment, is delighted to be exhibiting on Stand 106 at Making Pharmaceuticals...
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is…
